AcuraStem

Investors · 1

KE

Keiretsu ForumSan Francisco · $250K – $2M

DI

Diabetes Prevention Program24 shared keywords

PA

PatSnap19 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.

NC

NCT0510118713 shared keywords

VE

Verastem12 shared keywordsVerastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.

BI

Bioworld12 shared keywordsBioWorld publishes news and data on the biopharmaceutical and drug development industry, covering topics such as clinical trials, licensing deals, oncology pipelines, and gene therapies. It serves biopharma and life sciences professionals through industry reporting and market intelligence.

RE

ResearchGate11 shared keywords

QU

Quralis10 shared keywordsQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.

CO

Cowles_Investments_StemCentrx10 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.

CL

Clinicaltrialsarena10 shared keywordsClinical Trials Arena is an online news and information publication covering the clinical trials industry, including trends, regulatory developments, and industry events. It serves professionals working in pharmaceutical and clinical research.

BI

BioStem Technologies9 shared keywordsBioStem Technologies develops, manufactures, and commercializes perinatal tissue-based allografts for regenerative therapies, using its proprietary BioRetain processing method to preserve the tissue's biological properties. Products are made in an AATB-accredited, FDA-registered, cGMP-compliant lab and serve the regenerative medicine market.

Companies competing with AcuraStem for the same Google search keywords, organic and paid, via search-intersection analysis.

▶$5MofferedJun 2026 · Biotechnology

Rule 506(b)

CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTDprnewswire.com · Apr 2026 · press release

Officers, directors & promoters on the filing

• Samuel AlworthExecutive Officer, Director
• Qing Liu-MichaelDirector
• Paul AugustDirector
• Marcel van der BrugExecutive Officer
• Justin IchidaDirector

Offering amount

$5M

Minimum investment

$10K

Incorporated

Corporation, Delaware

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$3.1MraisedNov 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Justin IchidaDirector
• Samuel AlworthExecutive Officer, Director
• Paul AugustDirector
• Qing Liu-MichaelDirector

Offering amount

$3.1M

Amount sold

$3.1M

Minimum investment

$25K

First sale

Nov 2022

Incorporated

Corporation, Delaware

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$400KraisedNov 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Paul AugustDirector
• Justin IchidaDirector
• Samuel AlworthExecutive Officer, Director
• Qing Liu-MichaelDirector

Offering amount

$3.5M

Amount sold

$400K

Minimum investment

$25K

First sale

Nov 2022

Incorporated

Corporation, Delaware

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$380KraisedJun 2019 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Samuel AlworthExecutive Officer, Director
• Paul AugustDirector
• Justin IchidaExecutive Officer, Director
• Qing Liu-MichaelDirector

Offering amount

$2M

Amount sold

$380K

Minimum investment

$25K

Proceeds to insiders

$150K

First sale

Jun 2018

Incorporated

Corporation, Delaware, 2016

Federal exemptions

06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.